Contrasting XOMA Corporation (XOMA) and DNIB Unwind (BIND)

XOMA Corporation (NASDAQ: XOMA) and DNIB Unwind (NASDAQ:BIND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Profitability

This table compares XOMA Corporation and DNIB Unwind’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XOMA Corporation -329.42% N/A -155.46%
DNIB Unwind -201.34% -3,980.56% -123.62%

Risk & Volatility

XOMA Corporation has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500. Comparatively, DNIB Unwind has a beta of 2.79, meaning that its share price is 179% more volatile than the S&P 500.

Institutional and Insider Ownership

32.9% of XOMA Corporation shares are held by institutional investors. 3.0% of XOMA Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares XOMA Corporation and DNIB Unwind’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
XOMA Corporation $12.31 million 11.91 -$30.55 million ($7.32) -2.64
DNIB Unwind N/A N/A N/A ($1.98) -0.44

DNIB Unwind has higher revenue, but lower earnings than XOMA Corporation. XOMA Corporation is trading at a lower price-to-earnings ratio than DNIB Unwind, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for XOMA Corporation and DNIB Unwind, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA Corporation 0 2 2 0 2.50
DNIB Unwind 0 0 0 0 N/A

XOMA Corporation currently has a consensus price target of $17.00, indicating a potential downside of 11.87%. Given XOMA Corporation’s higher possible upside, equities analysts clearly believe XOMA Corporation is more favorable than DNIB Unwind.

Summary

XOMA Corporation beats DNIB Unwind on 7 of the 10 factors compared between the two stocks.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

DNIB Unwind Company Profile

DNIB Unwind, Inc., formerly BIND Therapeutics, Inc. is a shell company. The Company was engaged in developing targeted therapeutics, primarily for the treatment of cancer. As of August 1, 2016, the Company sold all of its assets. The Company’s subsidiaries include BIND (RUS) LLC and DNIB Subsidiary Corporation.

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply